Skip to main content

Contribute to a future without dementia with Lewy bodies

Do you want to contribute to a future without dementia with Lewy bodies? Apply now.

What we’ve achieved so far







Our dementia with Lewy bodies trials


Dementia with Lewy bodies


The goal of this study is to evaluate how safe and effective the new drug neflamapimod is for the treatment of participants with dementia with Lewy bodies (DLB). The study compares the effect of the new drug neflamapimod with the effect of a placebo (a drug without an active ingredient, a 'fake drug'). The study drug are capsules that you take with food.


levelDementia with Lewy bodies

durationStudy days are spread over 21 to 55 weeks

locationAmsterdam, Den Bosch or Zwolle

Contact us

Do you have questions, or would you like to know more about one of our studies? Contact us by telephone or email. We are happy to help you.

Our partners

Our mission is to eliminate brain diseases, but we cannot do that alone. That is why we work together with leading partners.